Laboratory Developed Tests Market
Report ID: SQMIG35A3638
Report ID: SQMIG35A3638
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35A3638 |
Region:
Global |
Published Date: June, 2026
Pages:
157
|Tables:
182
|Figures:
79
Global Laboratory Developed Tests Market size was valued at USD 11.80 Billion in 2024 and is poised to grow from USD 12.61 Billion in 2025 to USD 21.51 Billion by 2033, growing at a CAGR of 6.9% during the forecast period (2026-2033).
Laboratories developed tests market trends are also involved in performing these tests in accordance with CLIA regulations. There is a high demand for complex, quickly deployable tests to support precision medicine. Thus, the laboratory developed tests market can fill gaps created by existing commercial tests by providing customized molecular diagnostic, genomic diagnostic, and infectious disease diagnostic tests that that would otherwise be left unfilled. The transition of LDTs from basic biochemical/microbiological tests to complex NGS panels and companion diagnostic technologies has shifted the landscape. A history of flexibility in regulation has enabled innovation through LDTs and the COVID-19 pandemic has showcased the industry’s ability to quickly respond to public health crises through the utilization of LDTs and providing scalable systems for overcoming diagnostic shortages.
The fastest laboratories developed tests market growth is attributable to rapid advancement in technology; declining costs of sequencing and improved bioinformatics have increased analytical potency and decreased turnaround times for testing, causing the clinical community to adopt tests more rapidly. As such, laboratories are now beginning to deploy NGS panels and liquid biopsy assays to monitor cancer patients as this will allow clinicians to intervene earlier and create the evidence necessary to convince payers to reimburse. Additionally, point-of-care molecular platforms allow for testing of infectious disease out in the field, helping to reduce lengths of stay in hospitals due to infectious disease and also helping to prevent the spread of disease through outbreaks.
How is AI Enhancing Diagnostic Accuracy in the Laboratory-Developed Tests Market?
The laboratory developed tests industry is seeing enhanced diagnostic accuracy as a result of the use of artificial intelligence for pattern recognition, integration of multiple forms of data and standardization of interpretation of results. Key factors include machine learning models that are trained on large amounts of assay and imaging data, support systems that identify indeterminate test results for medical professionals to review and automated quality checks to lower the variability between laboratories. There are currently three main areas where artificial intelligence is being integrated into the laboratory developed testing space: molecular testing, digital pathology and advanced analytical platforms, all of which have improved signal detection and reduced ambiguity within a diagnosis through the use of artificial intelligence. As demand continues to grow for clearer actionable results and validation from laboratories, validated artificial intelligence tools will be increasingly attractive to laboratories that are looking for reproducible performance.
An example of artificial intelligence being utilized in the laboratory developed tests space is Myriad Genetics' launch of Prolaris in May 2026; a genomic test that utilizes artificial intelligence from digital pathology to aid in the assessment of prostate cancer risk. This will provide additional value to laboratory developed tests by improving clinical usefulness, expediting the laboratory's review and reporting processes, and enhancing the accuracy of the determination of the laboratory developed tests.
Market snapshot - (2026-2033)
Global Market Size
USD 11.8 Billion
Largest Segment
Molecular Diagnostics Tests
Fastest Growth
Genetic & Genomic Tests
Growth Rate
6.9% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global laboratory developed tests market is segmented by test type, technology, application, sample type, end user, complexity level and region. Based on test type, the market is segmented into molecular diagnostics tests, genetic & genomic tests, immunology tests, oncology tests, infectious disease tests and others. Based on technology, the market is segmented into PCR-based testing, next-generation sequencing (NGS), immunoassays, mass spectrometry, flow cytometry and others. Based on application, the market is segmented into oncology, infectious diseases, genetic disorders, autoimmune diseases, neurological disorders and others. Based on sample type, the market is segmented into blood, tissue, urine, saliva and others. Based on end user, the market is segmented into hospital laboratories, independent clinical laboratories, academic & research institutes and specialty diagnostic centers. Based on complexity level, the market is segmented into high-complexity tests and moderate-complexity tests. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
The Next Generation Sequencing (NGS) segment is a leading segment because it has capabilities in the area of multi-gene comprehensive genomic profiling (CGP) and is able to meet the complex diagnostic needs of precision medicine. Consolidating testing through the use of the NGS platform enhances the clinical utility of laboratory results and operational efficiency in addition to drivinginvestment in informatics and standardized reporting procedures. As a result, laboratories are prioritizing the development of NGS-based laboratory developed tests (LDTs) through the expansion of their genomic test menus.
The PCR based testing segment is rapidly growing as a result of high demand for rapid and low-cost molecular diagnostics. New digital PCR technologies, as well as next-generation multiplex real-time PCR technologies, facilitate workflows and create the ability to deploy testing in decentralized locations. Clarification of regulatory requirements for PCR LDTs enables faster access to the marketplace. These factors are creating new market opportunities for PCR LDTs across clinical settings and creating immediate commercial opportunities for scalable PCR LDTs.
The oncology segment continues to lead the biomarker testing services market due to the tailored biomarker panels needed to treat cancer, as well as the ability of laboratories to quickly create and implement laboratory developed tests through multi-gene profiling. The use of companion diagnostics, the need for Actionable Mutations, and the need to monitor treatment efficacy will also influence laboratory testing and the use of laboratory developed tests. The development of specialized assays based on therapeutics from collaboration between laboratories, clinical teams, and pharmaceutical partners will lead to the continued innovation and investment of LDTs in oncology.
The rapid growth of the infectious disease segment is a result of the ongoing demand for rapid pathogen detection, the increased use of multiplex panels, advancements in molecular assay design, and the demand for decentralized diagnostic methods that will provide rapid results. This continuous growth has allowed laboratories to quickly increase the size of their infectious disease laboratory developed test offerings and provides new opportunities for laboratories to maintain their test offerings and address changing public health issues.
To get detailed segments analysis, Request a Free Sample Report
North America is the largest market for laboratory developed tests globally due to a combination of advanced clinical infrastructure, focused investment in diagnostic innovation, and a regulatory environment that has historically allowed for the rapid deployment of laboratory-developed assays. Major academic medical centers and commercial reference laboratories have strong translational pipelines that accelerate adoption of specialized tests across disease areas. Novel assays are commercially viable with well established reimbursement pathways and sophisticated payer engagement. Robust collaborations between clinicians, biotechs and diagnostic manufacturers drive validation and uptake. Access to skilled laboratory personnel and state-of-the-art instrumentation underpin high test complexity capacity. Interest from investors and supportive academic networks also catalyze the translation of niche assays into clinical practice.
Laboratory developed tests market share in the United States is characterized by fast innovation, dense networks of academic and commercial labs, and a favorable environment for clinical translation. Diagnostic developers team closely with specialty clinicians to validate niche assays and expedite clinical adoption. Back commercialisation of complex tests are engagement of payers and accreditation frameworks for laboratories Extensive laboratory capacity and skilled workforce allow for high throughput and specialised testing services across clinical settings.
Laboratory developed tests market outlook in Canada is due to integrated healthcare systems and close ties between provincial laboratories and research institutions to validate and implement specialized assays in the region. Working together between networks allows for standardization and quality assurance of all laboratory services. Centralized reference laboratories and workforce development investment build capacity for complex testing panels, and access initiatives and regulatory pathways enable translation of laboratory developed tests into routine diagnostic workflows.
Across Europe, laboratory developed tests are growing fast, powered by a potent mix of clinical excellence, collaborative research networks, and evolving regulatory frameworks that encourage local innovation. National health systems and centralised laboratories allow integration of specialized assays into routine care and pan regional initiatives promote cross border validation and data sharing. The strong life science clusters and diagnostic manufacturers are working with academic centers to take biomarkers and molecular technologies and turn them into tests that can be deployed. The demand is driven by the growing focus on personalized medicine and proactive screening approaches that demand adaptable, high specificity assays, with targeted investment in laboratory capacity and quality management, which is aiding the market growth in major European markets. Better conversations between payers, regulators, and laboratory stakeholders are paving the way to clearer reimbursement and clinical evidence generation. Digital infrastructure improvements are enabling interoperable reporting and multicenter studies that validate test performance across health systems.
Laboratory developed tests market forecast in Germany has a strong industrial base in diagnostics, extensive clinical research networks and an accredited laboratory system that supports development and clinical implementation of specialized assays. University hospitals and reference laboratories validating novel molecular and immunoassays for complex disease management lead translational programs. Collaboration between hospital laboratories, diagnostic manufacturers and payers promotes assessment and integration of new tests into clinical pathways across care networks.
Laboratory developed tests market penetration in the United Kingdom is shaped by a combination of national health system priorities, local genomic and research hubs, and the presence of private laboratories that accelerate the uptake of new assays. Cross-sector partnerships enable rapid validation and clinical deployment of specialty tests, with procurement and integrated care networks for implementation. Enhance capacity for complex testing across care settings with a focus on precision medicine, innovation funding, and workforce expertise.
Laboratory developed tests market regional outlook in France is emerging from reinforced ties between public research institutes, hospital laboratories and growing private diagnostic providers focused on specialized assays. Improving laboratory infrastructure and reinforcing quality systems at the national level encourage local test development and clinical evaluation. Regional academic centers facilitate translational research. Changing reimbursement models and care pathways enable clinical uses of laboratory-developed tests in hospital and outpatient settings.
With the expansion of clinical laboratory infrastructure, focused government support for diagnostics and significant industry investment in translational research, Asia Pacific is cementing its role in the laboratory developed tests market. Advanced molecular and genomic capabilities and growing networks of hospital laboratories and private reference centers supporting validation and clinical deployment of specialty assays characterize leading markets. Regulatory and reimbursement environments are becoming more welcoming to locally developed diagnostics, and international partnerships with established diagnostic manufacturers help speed the transfer of technology. These dynamics enhance regional capacity for complex testing, promote localized assay innovation, and increase the integration of laboratory-developed tests into clinical practice across diverse healthcare systems. Investment in workforce training, laboratory automation and data standards will improve test reliability and enable the multicenter studies needed for wider clinical acceptance throughout the region.
Laboratory developed tests regional forecast in Japan is driven by sophisticated laboratory networks, strong domestic diagnostics manufacturers, and expertise in molecular and clinical assay development. University hospitals and specialty clinics collaborate with industry to validate complex tests for oncology and rare conditions. Regulatory pathways and quality standards support clinical evaluation, while investments in laboratory automation and workforce skill development enhance capacity to deliver advanced diagnostic services across hospital and community settings.
Laboratory developed tests industry trends in South Korea benefits from concentrated biotech clusters, diagnostic manufacturers, and integrated hospital laboratory systems that support assay development and clinical validation. Strong public-private collaboration fosters commercialization pathways, while emphasis on digital health and laboratory informatics enhances test development. Advanced manufacturing capability and international partnerships promote technology transfer, enabling laboratories to implement complex molecular and immunoassays across specialized clinical centers and broader diagnostic networks at scale.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rising Adoption Of Genomic Testing
Advancements In Molecular Diagnostics
Regulatory Uncertainty and Scrutiny
Reimbursement and Payer Challenges
Request Free Customization of this report to help us to meet your business objectives.
Active M&A and strategic partnerships, regulatory pressure on LDT oversight, and rapid technology innovation used by larger labs and new entrants to differentiate themselves are some of the key factors driving the competitive landscape of the global laboratory developed tests market. Examples include partnerships with platforms to advance NGS and proteomics, alliances with commercial labs to scale LDT rollouts and competition around exclusive test access and clinical integration.
Top Player’s Company Profile
Recent Developments in the Laboratory Developed Tests Market
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. As per SkyQuest analysis, the global laboratory developed tests market is propelled primarily by rising adoption of genomic testing, with a second driver being rapid advancements in molecular diagnostics and bioinformatics that lower costs and speed turnaround. North America remains the dominant region and NGS stands out as the leading segment, driven by demand for comprehensive genomic profiling and precision oncology. However, regulatory uncertainty and evolving oversight create a significant restraint by increasing validation burdens and slowing commercialization for smaller labs. Overall the market favors laboratories that combine multi-omics, AI-enabled interpretation, and scalable workflows to meet clinical needs and payer evidence requirements.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 11.8 Billion |
| Market size value in 2033 | USD 21.51 Billion |
| Growth Rate | 6.9% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Laboratory Developed Tests Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Laboratory Developed Tests Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Laboratory Developed Tests Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Laboratory Developed Tests Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Laboratory Developed Tests Market size was valued at USD 11.8 Billion in 2024 and is poised to grow from USD 12.61 Billion in 2025 to USD 21.51 Billion by 2033, growing at a CAGR of 6.9% during the forecast period (2026-2033).
The competitive landscape in the global laboratory developed tests market is shaped by active M&A and strategic partnerships, regulatory pressure on LDT oversight, and rapid technology innovation that larger labs and new entrants use to differentiate. Examples include platform partnerships to advance NGS and proteomics and commercial lab alliances to scale LDT rollouts, driving competition around exclusive test access and clinical integration. 'Quest Diagnostics', 'Labcorp', 'Sonic Healthcare', 'NeoGenomics', 'Natera', 'Guardant Health', 'Roche', 'Tempus AI', 'Myriad Genetics', 'Invitae', 'Fulgent Genetics', 'OPKO Health', 'Konica Minolta', 'Exact Sciences', 'Veracyte', 'Personalis', 'GeneDx Holdings', 'Baylor Genetics', 'Mayo Clinic Laboratories', 'ARUP Laboratories'
Genomic testing's integration into LDTs drives market expansion by enabling more precise disease characterization, tailored therapeutic selection, and early identification of genetic predispositions. Laboratories capitalize on these capabilities to develop specialized assays that meet clinician and patient needs, strengthening demand for customizable, clinically actionable tests. This trend encourages investment in assay development and validation, fosters collaborations between diagnostic developers and healthcare providers, and enhances the perceived clinical value of LDTs, thereby supporting broader adoption across clinical settings and stimulating sustained market growth.
Multi-Omics Integration: Adoption of integrated genomics, proteomics and metabolomics platforms is driving demand for laboratory-developed tests that provide broader biological insights. Laboratories increasingly combine multiple molecular layers to support precision diagnostics, enabling more informative disease stratification and therapeutic selection. This trend promotes partnerships between clinical labs and specialty technology providers, accelerates assay development, and shifts value toward differentiated test portfolios and consultative services. Market participants emphasize flexible workflows, data integration capabilities and demonstrable clinical utility to capture emerging clinical and commercial opportunities.
Why does North America Dominate the Global Laboratory Developed Tests Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
